Evidence map›Paper›PMID 27822750›Full record

ArticleDoklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections2016

Effects of intranasal administration of the peptide antagonist of type I vaniloid receptor (TRPV1) in the rodent central nervous system.

A O Tishkina, E K Mart'yanova, Yu A Logashina, Ya A Andreev, S F Khaibullina, E V Martynova, A A Rizvanov, N V Gulyaeva, E V Grishin

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

A O TishkinaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia. anna.tishkina@phystech.edu.
E K Mart'yanovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Yu A LogashinaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Ya A AndreevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
S F KhaibullinaKazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
E V MartynovaKazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
A A RizvanovKazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
N V GulyaevaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
E V GrishinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Institute of Bioorganic Chemistry · RUInstitute of Higher Nervous Activity and Neurophysiology · RUKazan Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intranasal administration of the polypeptide APHC3, an antagonist of the TRPV1 receptor, had acute anxiolytic and antidepressant effects, as well as an ability to modify the microglial response to proinflammatory stress and cytokine profile of the hippocampus. However, the acute antidepressant effect of the polypeptide was not related to the attenuation of neuroiflammation and probably had a different mechanism. The use of intranasal administration of the APHC3 peptide as a therapeutic approach aimed at decreasing depression symptoms needs additional studies in order to find the mechanism of action of this polypeptide in the central nervous system (CNS).

Indexed as

Administration, IntranasalAnalgesicsAnimalsAntidepressive AgentsAnti-Inflammatory AgentsCnidarian VenomsCytokinesDepressionDose-Response Relationship, DrugHippocampusIntercellular Signaling Peptides and ProteinsMalePeptidesRatsRats, WistarTreatment Outcomeanalgesic polypeptide HC3, Heteractis crispaAnalgesicsAntidepressive AgentsAnti-Inflammatory AgentsCnidarian VenomsCytokinesIntercellular Signaling Peptides and ProteinsPeptidesTrpv1 protein, ratTRPV Cation Channels

Identifiers

PMID27822750
OpenAlexW2550580462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.